TCA Cellular Therapy Report issue

For profit Phase 1 Phase 2
Founded: Covington LA United States (2004)
Status: Defunct (2011)

Organization Overview

First Clinical Trial
2007
NCT00518401
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

TCA Cellular Therapy, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

bone marrow derived mesenchymal stem cells (5 trials)

Drugs in Phase 1 Trials (1)

allogeneic adipose derived mesenchymal stem cell (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 1)

Arteriosclerosis (Phase 1)

Atherosclerosis (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Ischemia (Phase 2)

Motor Neuron Disease (Phase 1)

Myocardial Ischemia (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Sclerosis (Phase 1)

Spinal Cord Injuries (Phase 1)

Vascular Diseases (Phase 2)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2